Search
for
Sort by
Research 61–90 of 1000+
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- Dysregulation of Leukaemia Inhibitory Factor (LIF) Signalling Pathway by Supraphysiological Dose of Testosterone in Female Sprague Dawley Rats During Development of Endometrial Receptivity
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- Registrars and Fellows Update Session 2
- A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
- Alopecia Areata
- A Case of Alopecia Totalis with Lichen Planus Hypertrophicus Responded Excellently to Oral Tofacitinib-An Observation
- Alopecia Areata
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
- Upadacitinib for the treatment of alopecia areata – A case report
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
- Baricitinib for alopecia areata
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- Alopecia Areata: Current Treatments and New Directions
- 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
- The immunopathogenesis of Alopecia Areata
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2